01—Abstract
Summary
Summary of the 8-K filed October 29, 2025. Cited figures are marked; the original filing is the authoritative source.
United Therapeutics Corporation, a public benefit corporation (Nasdaq: UTHR), reported record financial results for the third quarter ended September 30, 2025, in a press release furnished as Exhibit 99.1 under Item 2.02 of this Form 8-K.
Total revenues grew seven percent year-over-year to $799.5 milliona from $748.9 million. Net income was $338.7 million, up 10 percent from $309.1 million, and diluted earnings per share were $7.16, up 12 percent from $6.39. Growth was led by Tyvaso DPI, which rose 22 percent to $336.2 million, and Orenitram, which rose 16 percent to $131.1 million.
Total Tyvaso revenues grew 10 percent to $478.0 millionb, partially offset by a decline in Nebulized Tyvaso and lower Unituxin sales. Operating expenses fell overall, with total selling, general, and administrative expense down 17 percent to $182.6 million, largely because the prior-year period included a $65.1 million litigation accrual related to Sandoz Inc. (the accrual balance was $73.3 million at September 30, 2025). Research and development expense rose 23 percent to $127.5 million, driven by manufactured organ and organ alternative projects and a $5.0 million drug delivery milestone payment.
The company's effective tax rate increased to 23 percent from 20 percent. Cash, cash equivalents, and marketable investments totaled $4,334.9 millionc at quarter-end, against total assets of $7,351.1 million and stockholders' equity of $6,590.2 million. Capital return and pipeline were also highlighted.
The company repurchased approximately $1.0 billiond of common stock under an accelerated share repurchase agreement with Citibank, N.A. in August 2025, and received 2,638,616 shares under the ASR agreements during the quarter. Management pointed to breakthrough results from the TETON-2 study in idiopathic pulmonary fibrosis as a potential driver of broader therapeutic reach and future growth.
02—Key points
Key Highlights
- Record third-quarter 2025 total revenues of $799.5 million, up 7 percent from $748.9 million in the prior-year quarter.
- Net income of $338.7 million, up 10 percent; diluted EPS of $7.16, up 12 percent from $6.39.
- Tyvaso DPI net product sales rose 22 percent to $336.2 million, driven mainly by higher quantities sold; total Tyvaso revenues grew 10 percent to $478.0 million.
- Orenitram revenues increased 16 percent to $131.1 million, with growth attributed to higher quantities sold and a price increase.
- Nebulized Tyvaso declined 11 percent to $141.8 million and Unituxin fell 22 percent to $47.9 million.
- Total SG&A decreased 17 percent to $182.6 million, reflecting the absence of the $65.1 million Sandoz litigation accrual recorded in the prior-year quarter; R&D expense increased 23 percent to $127.5 million.
- Repurchased approximately $1.0 billion of common stock under an accelerated share repurchase agreement in August 2025; cash and marketable investments totaled $4,334.9 million at September 30, 2025.
03—Questions
Frequently Asked Questions
What were United Therapeutics' key revenue results for the third quarter of 2025?
Total revenues were $799.5 million, up 7 percent from $748.9 million in the third quarter of 2024. Tyvaso DPI, the largest driver, rose 22 percent to $336.2 million, while total Tyvaso grew 10 percent to $478.0 million.
Why did operating expenses in SG&A decline so sharply?
Total SG&A fell 17 percent to $182.6 million. The prior-year quarter included a $65.1 million accrual related to ongoing litigation with Sandoz Inc., while the third quarter of 2025 recorded only $0.8 million for litigation accrual. Excluding that item, general and administrative expense rose 23 percent, driven by headcount growth, legal expenses and branded prescription drug fees.
How did the company's earnings and tax rate change?
Net income rose 10 percent to $338.7 million, and diluted EPS rose 12 percent to $7.16. Income tax expense was $99.3 million, and the effective tax rate increased to 23 percent from 20 percent, primarily due to year-over-year changes in actual and forecasted annual pre-tax earnings.
What capital return activity did the company complete?
The company entered into accelerated share repurchase agreements with Citibank, N.A. to repurchase approximately $1.0 billion of common stock in each of August 2025 and March 2024, totaling $2.0 billion. During the third quarter of 2025 it received 2,638,616 shares under these agreements.
What pipeline developments did management highlight?
Management cited breakthrough results from the TETON-2 study in idiopathic pulmonary fibrosis, which it said could significantly broaden the company's therapeutic reach and accelerate growth. R&D expense rose 23 percent to $127.5 million, driven by manufactured organ and organ alternative projects and a $5.0 million milestone payment for drug delivery technologies.
04—Continue